CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma
Part of paid clinical trials in Boston, Massachusetts.
- Sponsor
- Massachusetts General Hospital
- Study ID
- NCT00455897
- Phase
- PHASE2
- Status
- Terminated
Conditions
- Lymphoma, B-Cell
- Lymphoma, Diffuse
- Lymphoma, Non-Hodgkin
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- GM-CSF — DRUGGiven 11 days before day 1 of cycle 1 for 10 days
- CHOP — DRUGAdministered as part of standard care
- Rituximab — DRUGAdministered as part of standard treatment
Study Details
The primary goal of this study is to determine the effects (good and bad) of Granulocyte-macrophage colony stimulating factor (GM-CSF) in combination with Cytoxan, Adriamycin, Vincristine, Prednisone, Rituximab (CHOP-R) on diffuse Large B cell Non-Hodgkin's lymphoma (DLBCL). The standard of care for DLBCL is the combination of drugs known as CHOP-Rituximab (CHOP-R). The drugs that make up CHOP-R are the chemotherapy drugs cyclophosphamide, doxorubicin and vincristine, prednisone and rituximab. GM-CSF is a drug that stimulates the immune system by increasing the numbers of white blood cells. Previous research has shown that GM-CSF might help rituximab to be more effective in treating lymphoma.
Key Dates
- Start date
- Dec 31, 2006
- Status verified
- Jan 2018
- Primary completion
- Nov 30, 2007
- Completion
- Jul 31, 2011
Study Design
- Enrollment
- 3 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: GMCSF-RCHOP
Primary Outcome Measure
To determine the safety of GM-CSF when administered in combination with CHOP-R to patients with previously untreated diffuse large B cell non-Hodgkin's lymphoma. [ Time Frame: 2 years ]
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02115 | - |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02115 | - |
| Massachusetts General Hospital | Boston | Massachusetts | 02215 | - |
Find similar trials in Boston, MA
Related Studies
- Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic MalignanciesPHASE1 · Recruiting · Therapeutic Advances in Childhood Leukemia Consortium · Los Angeles, California
- Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND TrialRecruiting · Dana-Farber Cancer Institute · Boston, Massachusetts
- A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )PHASE1 · Not Yet Recruiting · Eli Lilly and Company · Duarte, California
- Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's DiseaseRecruiting · Stanford University · Stanford, California